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Abstract
Open reading frame (ORF) 45 of Kaposi’s sarcoma-associated herpesvirus (KSHV) is a tegument protein. A genetic analysis
with a null mutant suggested a possible role for this protein in the events leading to viral egress. In this study, ORF45 was
found to interact with KIF3A, a kinesin-2 motor protein that transports cargoes along microtubules to cell periphery in a
yeast two-hybrid screen. The association was confirmed by both co-immunoprecipitation and immunoflorescence
approaches in primary effusion lymphoma cells following virus reactivation. ORF45 principally mediated the docking of
entire viral capsid-tegument complexes onto the cargo-binding domain of KIF3A. Microtubules served as the major
highways for transportation of these complexes as evidenced by drastically reduced viral titers upon treatment of cells with
a microtubule depolymerizer, nocodazole. Confocal microscopic images further revealed close association of viral particles
with microtubules. Inhibition of KIF3A–ORF45 interaction either by the use of a headless dominant negative (DN) mutant of
KIF3A or through shRNA-mediated silencing of endogenous KIF3A expression noticeably decreased KSHV egress reflecting
as appreciable reductions in the release of extracellular virions. Both these approaches, however, failed to impact HSV-1
egress, demonstrating the specificity of KIF3A in KSHV transportation. This study thus reports on transportation of KSHV
viral complexes on microtubules by KIF3A, a kinesin motor thus far not implicated in virus transportation. All these findings
shed light on the understudied but significant events in the KSHV life cycle, delineating a crucial role of a KSHV tegument
protein in cellular transport of viral particles.
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Introduction
Kaposi’s sarcoma–associated herpesvirus (KSHV), also known
as the human herpesvirus 8 (HHV-8), is a human DNA tumor
virus [1]. KSHV is etiologically associated with the endothelial
neoplasm Kaposi’s sarcoma (KS) and with certain lymphoprolif-
erative disorders like primary effusion lymphoma (PEL) and
multicentric Castleman’s disease (MCD) [2,3]. KSHV infection of
cells by default establishes latency. During this phase, there is
expression of only a limited number of the viral (latent) genes
essential for maintenance of the viral genome with no production
of infectious virions [4]. Disruption of latency results in the
reactivation of the virus into the lytic phase, with expression of the
entire viral gene panel and production of infectious viral particles
[5,6]. These events thus ensure the propagation and transmission
of viruses to uninfected cells serving to maintain the infection [7].
Lytic phase is also essential in sustaining the population of latently
infected cells that otherwise would be quickly lost by segregation of
latent viral episomes as spindle cells divide [8]. The KSHV lytic
phase and constant primary infection of fresh cells is thus crucial
for both the viral tumorigenicity and the disease pathogenesis.
With the exception of viral DNA replication and viral gene
expression, other events that follow viral reactivation including
virus assembly, transportation and egress however have been
much less studied in KSHV. To gain more knowledge about these
events it thus becomes essential to identify the different virion
proteins and recognize their functional roles. For this purpose, we
purified extracellular KSHV virions from tetra deconyl phorbol
acetate (TPA)-induced BCBL-1 cells (that are latently infected with
KSHV) by double gradient ultracentrifugation and identified the
component virion proteins by a mass spectrometric analysis. By
this approach a total of 24 different virion-associated proteins were
identified by a mass spectrometric analysis including five capsid
proteins, eight envelope glycoproteins and eleven tegument or
putative tegument proteins [9].
Among the different virion proteins, the tegument proteins in
KSHV as well as in other related gamma herpesviruses have not
been well studied. Current knowledge of these proteins comes
mainly from studies on alpha and beta-herpesviruses wherein they
contribute to three essential functions in the viral life cycle. First,
some serve a regulatory function, modulating the host cellular
environment during the immediate-early phase of infection like the
virion host shutoff protein (UL41) of HSV-1 that degrades host
mRNA and shuts down the host translation program [10]. Second,
some play vital roles in transportation of capsids to the nucleus
along microtubules following virus entry into the host cell [11–13].
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events involving herpesviral assembly and egress including
transportation of viral complexes [14,15]. Based on these
evidence, the need arises to investigate the functional roles if any
of even the less studied KSHV tegument proteins.
One among these proteins in KSHV is ORF45, also recognized
as an immediate-early (IE) protein [16,17]. A vital role of ORF45
in events leading to viral egress following virus reactivation
emanated from two observations. First, we had generated an
ORF45-null recombinant KSHV using the bacterial artificial
chromosome (BAC) system by inserting a premature stop codon
into the ORF45 coding sequence [18]. Upon reconstitution into a
293T cell system followed by induction, this mutant produced a
much lower yield of progeny virions compared to the wild-type
virus though viral gene expression and DNA replication remained
unaffected [18]. This suggested that ORF45 could possibly have a
role to play in the stages subsequent to viral DNA replication and
viral protein synthesis, mostly involving transportation of viral
complexes toward viral egress. The second supporting observation
came from a yeast two hybrid (Y2H) screening employed to
identify ORF45 interacting cellular partners that revealed ORF45
to interact with cDNAs of KIF3A (in this study).
KIF3A is a subunit of kinesin-2, a microtubule (MT) plus-end-
directed motor protein. Kinesin-2 comprises two motor subunits,
KIF3A and either KIF3B or KIF3C, and a non-motor subunit,
KAP3(kinesin superfamily-associated protein-3) [19–21]. Kinesin-2
molecules are expressed ubiquitously and transport cargoes along
microtubules (MTs) from the nucleus to the cell periphery
[19,20,22]. KIF3A comprises of an N-terminal head (motor)
domain that attaches to and migrates along MTs and a C-terminal
tail that presumably functions as the cargo-binding domain [20,23].
In this study we thus explored the role and significance of
ORF45–KIF3A interaction in the possible transportation of KSHV
viral complexes along microtubules toward egress following
reactivation from latency. We found that ORF45 through its
interaction with the cargo-binding domain of KIF3A docked the
entire viral capsid-tegument complexes onto KIF3A which were
subsequently transported along microtubules for viral maturation
and egress. This to the best of our knowledge is the first report
attributing a definitive role of KIF3A in virus transportation.
Results
ORF45 interacts with KIF3A
Earlier studies with an ORF45-null mutant virus revealed that
disruption of ORF45 yielded 10-fold lowered titers of progeny
virions as compared to the wild-type virus though viral gene
expression and DNA replication remained unaffected [18]. This
finding suggested a role of ORF45 in virion assembly or egress. To
further explore the function of ORF45 in these processes, we
attempted to identify cellular proteins interacting with it. By an
Y2H screening we identified interferon regulatory factor-7 (IRF-7)
as an ORF45-associated protein with ORF45 antagonizing
interferon- related anti-viral responses [24]. Upon revisiting the
Y2H results, another cellular protein was also identified as an
ORF45-binding protein. This was KIF3A, a subunit of kinesin-2
and a microtubule (MT) plus-end-directed motor protein. KIF3A,
a 702 amino acid protein contains three domains, head (motor),
stalk and tail. Two prey plasmids isolated from the screening
contained cDNAs for the C-terminal fragments of KIF3A with
both fragments encompassing amino acids 409 to 702.
Interaction between ORF45 and KIF3A in cells was further
confirmed by co-immunoprecipitation (co-IP) experiments.
ORF45 and KIF3A expression vectors were used to co-transfect
293T cells. Forty-eight hours post-transfection, cells were lysed
and immunoprecipitated with an anti-ORF45 antibody. By a
Western blot, KIF3A was found to be immunoprecipitated with
ORF45, suggesting that the two proteins are physically associated
in a complex in cells (data not shown). The interaction of these two
proteins was also examined in BCBL-1 cells latently infected with
KSHV. Cell lysates prepared from TPA induced BCBL-1 cells
and immunoprecipitated with a mouse monoclonal anti-ORF45
antibody revealed KIF3A in the immunoprecipitate detected with
a rabbit anti-KIF3A antibody (Figure 1A, lane 3). As a control,
KIF3A was not immunoprecipitated with mouse IgG (Figure 1A,
lane 2). A reverse co-IP performed on cell lysates prepared from
TPA-induced BCBL-1 cells with a rabbit-polyclonal anti-KIF3A
antibody revealed immunoprecipitation of ORF45 with KIF3A
(data not shown). This thus proved the interaction between these
two proteins in the reverse direction, too.
Furthermore, the localization of ORF45 and KIF3A in BCBL-1
cells was also examined by immunoflorescence assay (IFA). BCBL-
1 cells induced with TPA for 48 hours were fixed and reacted with
mouse monoclonal anti-ORF45 and rabbit-polyclonal anti-KIF3A
antibodies. Both proteins were exclusively localized in the
cytoplasm (Figure 1B). The staining of ORF45 and KIF3A
completely overlapped, again suggesting that these proteins are
associated with each other in the cytoplasm of the cells.
Amino and carboxy termini of ORF45 interact with KIF3A
To further characterize the interaction between the two proteins,
we attempted to map the domains of ORF45 interacting with
KIF3A by Y2H and co-IP approaches. For the Y2H assay, full-
length and a series of ORF45 truncation/deletion mutants in
pACT2 vector (prey) were co-transformed with full-length KIF3A
in pAS2-1 vector (bait) into yeast cells. Yeast transformants positive
for prey-bait interaction were selected on plates lacking leucine,
tryptophan and histidine but containing 3-AT of an appropriate
concentration and assayed for b-galactosidase activity. The amino
(amino acids 1–115) and carboxy (amino acids 332–407) termini of
ORF45 interacted with KIF3A while the central domain (amino
acids 115–332) did not interact with KIF3A (Figure 2A, left panel).
Author Summary
Kaposi’s sarcoma–associated herpesvirus (KSHV) is a tumor
virus associated with Kaposi’s sarcoma (KS) and a spectrum
of other lymphomas. These tumor cells are usually latently
infected with this virus. The inactive virus in cells can get
reactivated, whereupon there is viral DNA replication and
viral protein synthesis. Newly synthesized proteins assem-
ble in an orderly fashion to form viral complexes that need
to be transported to the cell periphery for release and to
further infect fresh cells to maintain the infection. Events
that make up this important phase in the viral life cycle,
however, have been much less studied. In this study, we
show that a KSHV protein called the open reading frame
(ORF) 45 anchors newly assembled viruses onto a cellular
motor protein, namely KIF3A. These viruses are then
transported by KIF3A along microtubules which act as
major cellular highways (tracks), allowing for efficient
transportation of viral complexes toward the cell periph-
ery. Inhibition of any of these steps resulted in a reduced
transport of viral complexes reflecting as reduced viral
levels. Thus, this study has helped to delineate crucial
events involved in the transportation of newly assembled
KSHV virions and provides for attractive viral and cellular
targets that could be inhibited to reduce the virus burden.
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mutants were cloned in pCMV–Tag2 vector to express Flag-tagged
fragments. The truncation/deletion mutants were introduced into
293T cells by transfection. KIF3A was not included in the
transfection as it is ubiquitously expressed in all cells. Upon
confirmation of optimal and stable expression of the full-length and
the truncation mutants of ORF45 by a Western analysis, cell lysates
were immunoprecipitated with anti-Flag M2 affinity gel, followed by
a Western blot with an anti-KIF3A antibody. KIF3A was
immunoprecipitated with all the truncation mutants of ORF45 from
the C-terminus (mutants 1–115, 1–237, 1–332, 1–383) (Figure 2A,
right panel, lane 2, lanes 5–7) though with reduced affinities
compared to the full-length ORF45 (Figure 2A, right panel, lane
1). A similar finding was also seen with respect to truncations of
ORF45 from the N-terminus (mutants 238–407, 19–407, 77–407,
90–407, 115–407) (Figure 2A, right panel, lane 4, lanes 8–11). The
central domain (amino acids 115–332) however did not interact with
KIF3A (Figure 2A, right panel, lane 3). These findings thus indicated
only the amino (1–115) and the carboxy (332–407) terminals of
ORF45 to interact with KIF3A, consistent with the Y2H findings.
The cargo binding domain at the carboxy-terminal tail of
KIF3A interacts with ORF45
We next mapped domains of KIF3A interacting with OF45.
KIF3A, a 702 amino acid protein consists of an amino terminal
head (motor) domain (aa 1–355), a central stalk (aa 356–587) and a
cargo binding domain at the carboxy terminal tail (aa 588–702)
(Figure 2B). The motor domain has both the ATP and the
microtubule binding sites. The tail (cargo binding) domain
associates with cargoes transporting them along MTs.
Figure 1. Interaction of KSHV ORF45 with KIF3A. (A) BCBL-1 cells induced with TPA for 48 hours were lysed, and whole cell extracts (WCE) were
immunoprecipitated (IP) with mouse IgG (negative control) or mouse monoclonal anti-ORF45 antibody. The immunoprecipitates were analysed by
Western blotting (WB) with anti-ORF45 (upper panel) and anti-KIF3A antibodies (lower panel). Positions of the molecular mass standards (kDa) are
shown toward the left. (B) BCBL-1 cells treated with TPA for 48 hours were fixed and permeabilized. Cells were subjected to double-labeled IFA using
rabbit-polyclonal anti-KIF3A (red) and mouse monoclonal anti-ORF45 (green). The merged image is also shown.
doi:10.1371/journal.ppat.1000332.g001
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PLoS Pathogens | www.plospathogens.org 3 March 2009 | Volume 5 | Issue 3 | e1000332Figure 2. Mapping the domains in ORF45 and KIF3A that are required for their interaction. (A) The domains of ORF45 interacting with
KIF3A were mapped by both yeast two-hybrid (Y2H) and co-immunoprecipitation (co-IP) assays. The full-length or the truncation/deletion mutants of
ORF45 in either pACT2 (for Y2H) or pCMV-2Flag (for co-IP) vector were used as the prey plasmids. These were tested for interaction with KIF3A bait
cloned into pAS2-1 vector (for Y2H) or intrinsically present in 293T cells (for co-IP) by the respective assays. The left panel indicates the Y2H results (b-
galactosidase testing performed on yeast colonies cotransformed with the prey and bait plasmids and selected on plates lacking leucine, tryptophan,
and histidine with 3-Amino-1,2,4-triazole [3-AT]). The right panel shows co-IP results upon immunoprecipitation of 293T cell lysates (transfected with
the ORF45 expression plasmids) with anti-flag affinity gel followed by Western blot (WB) with rabbit-polyclonal anti-KIF3A antibody. Black bars
indicate ORF45 prey constructs that interacted with KIF3A, while hollow bars indicate constructs that did not interact with KIF3A. (B) Mapping the
domains of KIF3A interacting with ORF45 by an Y2H assay. The prey proteins, either the full-length or the truncation/deletion mutants of KIF3A, were
tested against the bait ORF45. Shown on the left are the results of Y2H assay (b-galactosidase testing performed on yeast colonies cotransformed
with the prey and bait plasmids and selected on plates lacking leucine, tryptophan, and histidine with 3-AT). Black bars indicate KIF3A prey constructs
that interacted with ORF45, while hollow bars indicate constructs that did not interact with ORF45.
doi:10.1371/journal.ppat.1000332.g002
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(KIF3A truncation/deletion segments in pACT2 vector) and the
bait (full-length ORF45 in pAS2-1 vector) were co-transformed
into yeast cells. Yeast transformants positive for prey-bait
interaction were selected as above and assayed for b-galactosidase
activity. The KIF3A truncation segments spanning amino acids 1–
400 (constituting only the motor domain), 400–600 (constituting
only the central stalk) and 1–600 (containing only the motor
domain and the stalk) failed to interact with ORF45. However, the
segment spanning amino acids 600–702 (constituting the cargo-
binding domain) interacted with ORF45. Additionally, deletions of
the motor domain (segment 400–702 with D 1–399) or the stalk
(1–702 with D 400–500 or D 500–600) did not block the affinity of
KIF3A to ORF45. But absence of the cargo-binding domain (1–
600 with D 601–702) abolished the interaction of KIF3A with
ORF45 (Figure 2B). These results suggested that ORF45
specifically interacted with the cargo-binding domain of KIF3A.
KIF3A associates with entire KSHV capsid-tegument
complexes but not with envelope glycoproteins
ORF45 specifically binds to the KIF3A subunit of Kinesin-2
and also has been shown to be tightly associated with KSHV
tegumented capsids through interaction with many other tegu-
ment proteins including ORF64 and ORF63 and capsid proteins
ORF 62 [25]. Thus we hypothesized that ORF45 may mediate
association of assembling viral particles to the motor molecules
and play a role in their transportation along microtubules during
virion maturation. To validate the model, we asked if KIF3A
associates with only ORF45 or with a whole capsid-tegument
complex. We addressed this question by immunoprecipitating cell
extracts obtained from TPA induced 293T cells harboring wild-
type KSHV (BAC36) with an anti-KIF3A antibody. Upon
analyzing the immunoprecipitates, we found that in addition to
ORF45, other tegument proteins (ORFs 33 and 64) and capsid
proteins (ORFs 62 and 65) were co-precipitated with KIF3A
(Figure 3A, lane 4). The viral envelope glycoproteins (gB and gH)
however failed to co precipitate with KIF3A (Figure 3A, lane 4).
The whole cell extracts (WCE) showed the expression of all the
analysed proteins (Figure 3A, lane 1). A similar experiment
performed on induced BCBL-1 cells also revealed identical
findings (data not shown). Thus these observations suggested that
KIF3A is associated and thereby involved in the transportation of
only the entire viral capsid-tegument complexes and not the
envelope glycoproteins which are transported separately from
tegument-capsid particles in the cytoplasm.
ORF45 mediates the association of KIF3A with the KSHV
capsid-tegument complex
We next investigated the specific role of ORF45 in associating
viral particles to KIF3A. There were two possibilities (1) ORF45
could just be one among the many KSHV virion proteins
interacting with KIF3A; (2) ORF45 probably mediates the
association of viral complexes with KIF3A. Hence to delineate
the role of ORF45 in this process, we performed a parallel
immunoprecipitation assay on cell lysates collected from induced
293T cells carrying an ORF45-null mutant (BAC-stop45). In the
absence of expression of ORF45 both the tegument and the capsid
proteins failed to coprecipitate with KIF3A (Figure 3A, lane 6),
providing a strong evidence that the viral capsid-tegument
complexes docked onto KIF3A through ORF45. The lack of co-
precipitation of tegument-capsid proteins with KIF3A in the
ORF45-null mutant also could have been due to a defect in
tegument-capsid complex assembly as a result of lack of functional
ORF45 protein. To investigate this posibility, we also performed a
co-IP with anti-ORF65 antibody with cell lysates from both
BAC36 and BAC-stop45-carrying cells, followed by Western
analyses with specific antibodies to some virion proteins. Intact
viral capsid-tegument complexes as evidenced by presence of
ORFs 65, 62, 33, and 64 were detectable in the immunoprecip-
itates obtained from both wild-type (Figure 3B, lane 4) and the
ORF45-null mutant (Figure 3B, lane 6) viruses. Taken together,
these results proved that the absence of functional ORF45 does
not disrupt viral tegument-capsid complex assembly processes, but
impairs the loading of the viral complexes on kinesin-2 molecules.
KSHV requires intact microtubules for transport of viral
complexes toward egress
Studies with other herpesviruses like HSV and pseudorabies
virus (PrV) have shown the requirements for an intact MT
network to ensure transport of viral complexes toward cell
periphery for viral egress [11,26–28]. Additionally, from the
association of the KSHV capsid-tegument complexes with KIF3A,
a motor protein moving along microtubules, it only seemed logical
to investigate the role of MTs in the transportation of the viral
complexes following reactivation. To address this issue, BCBL-1
cells were treated with increasing doses (0.5, 5.0, 10.0 mM) of
nocodazole, a microtubule depolymerizing drug [29], followed by
induction of viral lytic cycle with TPA. Four days post-induction,
virions were pelleted and viral copy numbers estimated by a real
time PCR. With increasing concentration of nocadazole in a
nontoxic range, there was an appreciable decrease in the
extracellular virion titers down to a level of 3.5610
5 copies/ml
amounting to a 8 fold reduction compared to the levels obtained
with nocadazole untreated and induced BCBL-1 cells (Figure 4).
Hence damage to the MT architecture through depolymerization
by nocadazole had contributed to inefficient transport of the viral
complexes reflecting as reduced viral titers.
To ensure that the decrease in viral titers seen was not due to
the toxic effects of the drug permanently damaging the cellular or
the virion architecture, we also performed a nocodazole removal
(washout) experiment in parallel. Herein cells treated with 5 mMo f
the drug were washed twice with PBS and once with serum-free
medium to ensure removal of the drug followed by induction with
TPA. Such drug removal studies have shown to result in rapid
repolymerization of MTs within a short time span [30–32]. In our
study following the drug removal, a reversal of its effect was
evidenced by build up of virion titer levels comparable to that of
the untreated but induced cells (Figure 4). Thus drug removal had
resulted in MT repolymerization, resuming efficient transport of
the viral complexes. To ensure that the decrease in viral titers was
not due to nocodazole treatment irreversibly damaging the virion
architecture or preventing viral tegument-capsid complex forma-
tion, nocodazole-treated and TPA-induced BCBL-1 cells were
immunoprecipitated with anti-ORF65 antibody. In addition to
ORF65, other capsid (ORF62) and tegument (ORFs 45, 64, and
33) proteins were detected in the immunoprecipitates by Western
blot with specific antibodies, indicating the presence of intact
tegument-capsid complexes in nocodazole-treated cells (data not
shown). This proved that nocodazole did not damage the virion
architecture.
To further investigate if KSHV particles are associated with
MTs, a double-labeled IFA was performed. TPA induced BCBL-1
cells were fixed and permeablized. MTs and viral capsids were
detected with mouse monoclonal anti-tubulin and rabbit-poly-
clonal anti-ORF65 antibodies respectively with anti-mouse IgG-
Alexa Flour 488 (green) and anti-rabbit–IgG-Texas Red (red)
secondary antibodies. Upon confocal microscopic examination, a
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intervals from the bottom to the top of the image. At each interval,
the two channels were recorded sequentially and/or simulta-
neously and images acquired. The individually acquired MT
(green channel) and the viral capsid (red channel) staining in a cell
are shown in Figure 5A and 5D, and 5B and 5E, respectively,
representing two different optical sections at which images were
acquired. The merged image shows viral capsids as red structures
localized along the MTs (Figure 5C and 5F). A reconstructed 3-D
image of the cell constructed revealed close association of viral
particles with MTs (Video S1).
IFA was also performed on BCBL-1 cells following nocodazole
treatment. Results are shown in Figure 5G–5I and Video S2. First
of all, the absence of microtubule network was shown with anti-
tubulin antibody staining in the cells treated with nocodazole.
Second, we expected to see majority of the viral particles localized
only around the perinuclear region. But as shown in Video S2,
absence of staining with anti-tubulin prevented us from getting a
definitive conclusion. In addition, the cell morphology is another
reason for the difficulty to locate the viral particles within the
cytoplasm as the nuclear membrane could have been only
separated by a few micrometers from the plasma membrane.
Thus the viral particles seen could actually have been localized to
the perinulear zone, but due to the above phenomenon it might
have been difficult to demonstrate it. However, images of the cell
taken at different ‘Z’ depths do in fact show viral particles to be
more concentrated toward the center of the cell (i.e., the nucleus).
Further IFA performed on cells following nocodazole removal
gave a picture similar to that of the drug-untreated control with
viral particles associated with microtubules (data not shown).
Functional significance of ORF45–KIF3A interaction
To investigate the significance of this interaction in the KSHV
life cycle, we employed a dominant negative (DN) mutant
approach. Such approaches have been often used for functional
studies of kinesins, including kinesin-2 [33–35]. One among the
Figure 3. Association of KIF3A with KSHV capsid-tegument complexes mediated by ORF45. Stable 293T monolayers harboring either
wild-type (BAC-36) or ORF45-null mutant (BAC-stop45) KSHV were induced with TPA for 48 hours. (A) Whole cell extracts (WCE) from both the BAC36
(lane 1) and the BAC-stop45 mutant (lane 2) were immunoprecipitated with rabbit IgG (lanes 3 and 5) or rabbit-polyclonal anti-KIF3A antibody (lanes
4 and 6). The immunoprecipitates were subsequently analysed by Western blotting with anti-KIF3A and antibodies to the KSHV virion tegument
(ORF45, ORF33, and ORF64), capsid (ORF62 and ORF65) proteins, and envelope glycoproteins (gB and gH). (B) The same cell lysates were also
immunoprecipitated with anti-ORF65 antibody, and the precipitates were analyzed by Western blotting with antibodies against different capsid and
tegument proteins as indicated.
doi:10.1371/journal.ppat.1000332.g003
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deleted. This mutant is neither able to hydrolyze ATP nor bind to
microtubules hence unable to migrate. The KIF3A fragment
(amino acids 409–702), isolated from our Y2H screening as
interacting with ORF45, could theoretically work as a DN mutant
of KIF3A. This fragment is unable to migrate along microtubules
as it lacks the N-terminal motor domain (spanning amino acids 1–
355, Figure 6A) but could still compete with wild type KIF3A in
binding to ORF45 (and thereby viral complexes) due to the intact
C-terminal cargo-binding domain.
First, to test if the KIF3A-DN mutant binds to viral particles,
BCBL-1 cells were electroporated with the KIF3A-DN mutant
plasmid (cloned into a pCMV-flag tagged vector) along with RTA-
expression vector (pCR3.1-ORF50 plasmid). Forty-eight hours post-
transfection, celllysates obtained were immunoprecipitated with anti-
flag M2 Affinity gel. In addition to ORF45, other virion tegument
(ORFs 64, 33) and capsid proteins (ORFs 62, 65) were detected by a
Western analysis along with the flag-tagged KIF3A-DN protein.
However, the DN protein was not able to bind to microtubules as
seen by the absence of alpha-tubulin in the immunoprecipitate
(Figure 6B). This suggested that though the DN mutant is bound to
viral particles it still cannot transport them along microtubules due to
the absence of the N-terminal motor domain.
We then tested if this DN mutant is able to block KSHV
particle assembly and release. The KIF3A DN mutant at
increasing concentrations (0.5, 1.0, 2.0 and 10.0 mg) was
introduced into BCBL-1 cells by electroporation along with
pCR3.1-ORF50 plasmid for induction into the lytic phase. Four
days post-transfection, extracellular viral particles were collected
and quantified by a real-time PCR [18]. With increasing inputs of
the KIF3A DN mutant, there was a noticeable decrease in the
extracellular virion titers down to a level of 3.7610
5 copies/ml,
amounting to a 7-fold reduction compared to levels obtained with
DN-untreated but -induced BCBL-1 cells (Figure 6C). KIF3A DN
mutant thus effectively inhibited the KIF3A-ORF45 interaction
indicating that the ORF45-mediated interaction of viral particle to
kinesin-2 is crucial for the transport of particles toward viral egress.
To rule out the possibility that the decrease in virion titers seen
with the KIF3A DN mutant could possibly have been due to its
generalized cytotoxic effects on the cells or other detrimental
effects on the viral components, a similar experiment was also
performed in 293T cells infected with KSHV or HSV-1. We
hypothesized that HSV-1 could serve as an effective negative
control based on earlier studies which have documented only the
requirements of kinesin-1/kinesin heavy chain (KHC) protein and
not that of KIF3A in the transportation of HSV viral complexes
toward egress [36–38]. Using an RNA interference approach, we
also showed that KHC indeed has a significant role in HSV-1
transportation toward egress and that KIF3A plays no discernable
role in HSV-1 intracellular transportation (Figure S1). These data
clearly illustrated that HSV-1 could be employed as an effective
negative control for the KIF3A DN mutant studies.
293T cells transfected with increasing concentrations of the
KIF3A DN mutant plasmid (0.5, 1.0, 2.0 and 10.0 mg) were
infected with either KSHV (at 50 genomes per cell) or with HSV-1
(5 Pfu/cell). With KSHV, following infection, cells were induced
with TPA and virion titers estimated. With increasing inputs of the
DN mutant, virion titers dropped to about 1.1610
5 copies/ml
Figure 4. Effect of nocodazole on KSHV virion titers. BCBL-1 cells were treated with increasing concentrations (0.5, 5.0, 10.0 mM) of the
microtubule depolymerizing drug nocodazole and induced with TPA. For nocadazole washout experiments, cells were treated with 5 mM of the drug,
washed thoroughly to ensure complete removal of the drug, and then induced with TPA. Following induction, extracellular KSHV virions were
collected and concentrated 100-fold. Virus stocks were treated with Turbo DNase I and viral DNAs extracted. KSHV genomic DNA concentration was
estimated by a real-time PCR along with external standards of known concentrations of the viral DNA using primers against the ORF73 gene and
expressed as viral DNA copy numbers per milliliter (ml) of the supernatant.
doi:10.1371/journal.ppat.1000332.g004
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DN untreated but induced 293T cells (Figure 6D), similar to that
seen with BCBL-1 cells. With HSV-1, at three different time
points (18, 24 and 36 hours post-infection), extracellular virions
were collected and titers measured by a real-time PCR. There was
no noticeable decrease in titers even with increasing concentra-
tions of the KIF3A DN mutant with levels similar to that of the
DN untreated control (Figure 6E). Introduction of the KIF3A DN
mutant had no detrimental effect on the cells or HSV-1 suggesting
that the decrease in viral titers seen with KSHV in both BCBL-1
and 293T cells was specifically attributable to the competitive
effect of the KIF3A DN on wild-type KIF3A in binding to
ORF45. This clearly points out to the crucial role of KIF3A-
ORF45 interaction in pathways leading to KSHV egress.
Knockdown of KIF3A expression by shRNA-mediated
silencing significantly halts KSHV egress
Though the KIF3A DN mutant reduced the KSHV viral egress
considerably, we did not notice a complete abrogation of viral
egress. There could be two possibilities for this scenario: (i) though
greatly reduced by the DN mutant, some full-length KIF3A could
still interact with ORF45 mediating viral transportation; (ii) other
kinesin motors may also contribute to transportation of viral
complexes. To address the first possibility, we attempted to
knockdown KIF3A expression in cells through a short-hairpin
RNA (shRNA)-based approach and examine its effect on KSHV
transportation and hence egress. A Mission shRNA gene set
against human KIF3A was purchased from Sigma-Aldrich. The
Mission shRNA system is a lentiviral vector based RNA
interference library against annotated human genes, which
generates siRNAs in cells and mediates gene specific RNA
interference for extended periods of time. The KIF3A shRNA
set consists of four individual shRNA lentiviral vectors against
different target sites of KIF3A mRNA sequence (clone #1 was
directed against the 39 UTR and the clone #s 2–4 targeting the
coding sequence). After introduction into BCBL-1 cells by
lentiviral transduction, all the four KIF3A shRNA clones were
found to effectively down-regulate KIF3A expression to almost
Figure 5. Confocal microscopic examination revealing association of KSHV viral particles with microtubules. BCBL-1 cells induced with
TPA for 48 hours were fixed, permeablized, and stained with mouse monoclonal anti-tubulin a and rabbit-polyclonal anti-ORF65 antibodies,
respectively. The secondary antibodies were anti-mouse IgG-Alexa Flour 488 (green) and anti-rabbit-IgG-Texas Red (red). The two channels were
recorded sequentially and/or simultaneously and images acquired. The individually acquired MT (green channel) (A,D), viral particle (red channel)
(B,E), and the merged images (C,F) of a cell are shown. The upper and middle rows represent two different optical sections at which images were
acquired from a series of sections collected at 0.32 mm intervals from the bottom to the top of the image. IFA was also performed on BCBL-1 cells that
had been treated with 5 mM of nocodazole and induced with TPA (the lower row). The individually acquired MT (G), viral capsid (H), and merged
images (I) for a nocodazole-treated cell are shown.
doi:10.1371/journal.ppat.1000332.g005
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BCBL-1 cells stably expressing the KIF3A and control shRNAs,
respectively, were induced with TPA. Four days post-induction
extracellular virions were collected and titers estimated by a real-
time PCR. All of the four KIF3A shRNA clones were effective in
drastically reducing the extracellular virion titers down to a level of
about 1610
5 copies/ml amounting to a nearly 24 - 25 fold
reduction compared to the controls (BCBL-1 cells transduced with
control shRNA/TPA induced and untransduced BCBL-1 cells/
TPA induced) (Figure 7B). The reductions were more pronounced
than that with the DN approach.
To ensure that the decrease in viral titers was not due to any
deleterious effects of the introduced lentiviruses or the shRNA
sequences on KSHV replication, intracellular KSHV genomic
DNA were analyzed at forty-eight hours post-induction by a real-
time PCR. The viral genome copies were normalized to GAPDH.
Levels of viral replication were not significantly altered in the
lentivirus transduced cells compared to non-transduced/TPA
Figure 6. Functional significance of KIF3A-ORF45 interaction. (A) Schematic representation of the wild-type (full-length) and the dominant
negative (DN) mutant of KIF3A. (B) Association of KIF3A DN mutant with KSHV tegument-capsid complexes. BCBL-1 cells were electroporated with
the KIF3A-DN mutant plasmid along with the RTA-expression vector. Forty-eight hours post-transfection, whole cell extracts (WCE) were
immunoprecipitated with mouse IgG (negative control) or anti-flag M2 Affinity gel. The immunoprecipitates were subsequently analysed by Western
blotting with antibodies against flag tag, capsid, and a-tubulin proteins as indicated. (C) Increasing concentrations of the KIF3A DN mutant
expression plasmid were electroporated into BCBL-1 cells along with 10 mg of pCR3.1-ORF50 or (D) transfected into 293T cells followed by KSHV
infection and subsequent TPA induction. Extracellular KSHV virions were collected and concentrated 100-fold. Virus stocks were treated with Turbo
DNaseI, viral DNAs extracted, and KSHV genomic DNA concentration estimated by a real-time PCR along with external standards of known
concentrations of the viral DNA with primers against the ORF73 gene. Viral titers were expressed as viral DNA copy numbers per milliliter (ml) of the
supernatant. (E) 293T cells were transfected with increasing concentrations of the KIF3A DN mutant and infected with HSV-1. Extracellular virions
were collected at three different time-points (18, 24, and 36 hours post-infection), and the HSV-1 genomic DNA was extracted and quantitated by a
real-time PCR along with external standards of known concentrations of the viral DNA with primers directed against the UL30 gene and expressed as
the respective viral DNA copy numbers per ml of the supernatant. Viral titers obtained from the 18, 24, and 36 hour time-point samples are
represented as black, light grey, and dark grey bars, respectively.
doi:10.1371/journal.ppat.1000332.g006
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represents most likely a direct effect of KIF3A knockdown.
Furthermore, this set of KIF3A shRNAs did not affect HSV-1
egress in 293T cells while the HSV-1 production was dramatically
inhibited by three shRNAs that target KHC/kinesin-1 (Figure S1).
Overall, the findings from the KIF3A knockdown studies clubbed
with the conclusions from the DN mutant studies definitively point
to a very pivotal role of KIF3A in transportation of KSHV
tegumented capsids, establishing the specificity of KIF3A in
KSHV transport.
As to the second possibility that other kinesins may also
contribute to KSHV intracellular transport, we also included a set
of shRNAs against KHC (kinesin-1) in the studies to look into the
role of KHC in KSHV transport. KHC is the typified and the
most widely studied among the kinesin group of proteins and it has
been definitively implicated in transportation of related herpesvi-
ruses like HSV-1 [36–38] and many other viruses including
vaccinia [39] and West-Nile virus structural proteins [40]. Three
of four KHC shRNA clones effectively down-regulated KHC
expression to almost undetectable levels as compared to the
control (Figure 7A and Figure S1A). None of the three KHC
shRNA clones exhibited any drastic effects on KSHV egress to
that seen with KIF3A but decreasing the viral egress very slightly
(just about 1-fold) (Figure 7B). This finding thus does not exclude
the utility of KHC in KSHV transport and suggests possibly a very
minor role for KSHV egress. Although it is difficult to conclude
that kinesin-2 is the only motor molecule necessary and sufficient
for KSHV egress as human kinesin family consists of at least 14
different members, our data indicate that KIF3A remains the
primary mediator.
Discussion
An ORF45-null mutant virus was profoundly defective in the
release of extracellular mature infectious virions though with no
obvious defects in overall gene expression and lytic DNA
replication, suggesting a role of ORF45 in virion assembly and
egress [18]. Compelling evidences presented in this report
substantiate this possible role by revealing the requirement of
ORF45 in the kinesin-2-mediated transport of assembled viral
particles along microtubules after nuclear egress. The evidences
are (i) ORF45 specifically interacts with the cargo-binding domain
of KIF3A and is colocalized with the cellular motor protein in the
cytoplasm; (ii) Entire viral tegument-capsid complex was associ-
ated with KIF3A with ORF45 mediating the association; (iii)
Intact microbutules were required for transport of viral complexes
toward egress as demonstrated by nocadazole treatment and IFA;
(iv) Disruption of KIF3A-ORF45 interaction with a headless DN
mutant of KIF3A or through knockdown of endogenous KIF3A
expression by siRNAs noticeably decreased KSHV egress reflected
as appreciable reduction in the release of extracellular virions; (v)
Knockdown of KHC expression had no appreciable effects on the
viral egress demonstrating the specificity of KIF3A in KSHV
transportation.
Based on these evidences a model for the role of ORF45 in
virion maturation and egress has been presented (Figure 8). In this
model, after nuclear egress, KSHV capsids acquire tegument
proteins including ORF64, ORF63 and ORF45 in the cytoplasm.
ORF45 on the capsid-tegument particles recruits KIF3A and
mediates loading of the viral particles onto kinesin-2. Subsequent-
ly, viral particles are transported along microtubules in the
cytoplasm from the perinuclear region to the cell periphery or
trans-golgi network (TGN) membrane where envelopment and
egress occur (Figure 8). Transportation and acquirement of
envelope glycoproteins is independent to that of the KIF3A
transportation of viral tegument-capsid complexes as evidenced in
our study wherein KIF3A failed to associate with glycoproteins (gB
and gH). Similar findings have also been observed in HSV-1
where the anterograde transport of unenveloped capsids and the
glycoproteins in axons involved dissociated pathways [27,36–
38,41].
Similar to ORF45, an identical role of tegument proteins in
transportation of viral complexes has been shown in related
herpesviruses like HSV-1 and PrV. Specific tegument proteins of
HSV-1 like US11 and UL56 interact with related kinesins like the
kinesin-1 motors playing vital roles in the anterograde transport of
viral complexes along microtubules in the axons [36–38,42].
Outer tegument proteins pUL47, pUL48 and pUL49 of PrV
mediate its anterograde transport [11]. The major tegument
protein pUL36 in both HSV and PrV contributes to the MT-
dependent transport of capsids during egress [26,28,43].
Homologues of KSHV ORF45 though found in other members
of gamma herpesviruses, are not present in alpha- and beta-
herpesviruses. An earlier study from our laboratory revealed a role
of ORF45 in antagonizing interferon antiviral defenses. KSHV
ORF45 interacted with IRF-7 efficiently suppressing virus-
mediated interferon (IFN) gene expression [24]. But the ORF45
counterparts of Epstein-Barr virus (EBV) and Rhesus monkey
Rhadinovirus (RRV) did not interact with IRF-7 (our unpublished
data), suggesting that interaction with IRF-7 and inhibition of its
activation is probably a function unique to KSHV ORF45. In
contrast, KIF3A in addition to KSHV ORF45 also interacted with
its analogues in EBV and RRV by both Y2H and co-IP (data not
shown). The second function of ORF45 in virus transport through
interaction with KIF3A could thus be uniformly conserved across
all gamma herpesviruses.
An amino acid sequence alignment of ORF45 sequences from
related gamma-herpesviruses performed with the ClustalW
software (NCBI website) revealed a significant conservation of
amino acids in the N-terminal and the C-terminal domains of the
protein across the spectrum (data not shown). This observation
further substantiated our ORF45 mapping data in KSHV wherein
we detected only these highly conserved domains (amino acids 1–
115 and 332–407; amino and carboxy terminals respectively) of
ORF45 to interact with KIF3A, while the sparsely conserved
middle domain (amino acids 115–332) failed to associate with
KIF3A.
The C-terminal region (spanning amino acids 600–701) of
KIF3A was found to interact with ORF45. This region has been
predicted to be the possible cargo-binding domain of the protein
[20,23]. Similar interactions of viral proteins with the cargo-
binding domain of other kinesins have also been reported in
additional viruses including West-Nile virus [40], HIV-1 [44] and
other herpesviruses like HSV-1. Interestingly in HSV-1, US11
tegument protein interacted with the heptad repeat cargo-binding
domain of Kinesin-1 [36] contributing to the anterograde
transport of nucleocapsids along axons. Interactions of the
cargo-binding domain of KIF3A with viral proteins have not
been reported thus far. However other cargoes, like the PAR-3
protein (a protein complex functioning in various cell polarization
events) [35] and GADD34 (possibly involved in transcription and
DNA recombination) [23] specifically interacted with the cargo-
binding domain of KIF3A.
To assess if the KIF3A-ORF45 interaction is crucial for the
virus in transportation toward viral egress, we further probed their
interaction dynamics by two different approaches. The first
approach involved the use of a DN mutant of KIF3A that lacks
the motor domain but retains the cargo-binding domain. This
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PLoS Pathogens | www.plospathogens.org 10 March 2009 | Volume 5 | Issue 3 | e1000332Figure 7. Knockdown of KIF3A and KHC by short-hairpin RNA (shRNA)–mediated silencing and the effects on KSHV egress and
extracellular viral titers. (A) Inhibition efficiency of KIF3A and KHC expression in BCBL-1 cells. Two sets of shRNA constructs, each consisting of four
individual shRNA lentiviral vectors in pLKO.1-puro plasmids against different target sites of KIF3A (KIF3A shRNA clone #s 1–4) and KHC (KHC shRNA
clone #s 1–4), respectively, and a non-targeting control shRNA that activates the RNAi pathway without targeting any known human gene were
introduced into BCBL-1 cells through lentiviral transduction in the presence of polybrene. Cells were selected through puromycin (2 mg/ml) selection
for a week and then tested for effective knockdown of the respective proteins by a Western blot (WB) performed on the whole cell extracts using
anti-KIF3A (rabbit-polyclonal, left panel) and KHC (rabbit-polyclonal, right panel). A WB for b-actin protein detection was also performed as an internal
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ORF45 hence reducing the transport of viral complexes toward
viral egress reflecting as a noticeable fall in virion release. Two
valid observations arose from this approach: (i) KIF3A–ORF45
interaction is of definitive significance in the transportation of
KSHV viral capsid-tegument complexes; (ii) it demonstrates a
potential value of the DN mutant in a peptide therapy to treat
KSHV-associated diseases which could be further investigated.
With the DN mutant approach, we however did not notice a
total abrogation of viral egress. This finding was expected, as the
DN mutant can only competitively inhibit the full length KIF3A-
ORF45 interaction and not totally abolish the interaction. We
hypothesized that a much clearer picture on the contribution of
KIF3A in transportation of viral complexes could only arise by
approaches that tend to totally inhibit its interaction with ORF45.
This was made possible by attempting to knockdown the
endogenous KIF3A expression in BCBL-1 cells. A lentivirus based
approach was employed to generate cells harboring the KIF3A
shRNA sequences integrated into the host cell genome. This
allowed for the stable and long-term gene down regulation,
overcoming the difficulties associated with only a transient gene
knockdown following direct transfection of small interfering RNA
(siRNA). Stable knockdown of KIF3A expression manifested as a
highly significant reduction in viral egress, more pronounced than
that encountered with the DN approach.
Human kinesins constitute a large family of motor proteins with
at least 14 members. Our data through gene knockdown studies
suggest that kinesin-2 is a major vehicle for KSHV intracellular
transport while kinesin-1 (KHC) is crucially responsible for HSV-1
transport. Although the likelihood of other kinesins contributing to
KSHV and HSV-1 transport in minor roles cannot be ruled out,
the fact that KSHV and HSV-1 egress was clearly not
compensated by other kinesins during the shRNA knockdown of
KIF3A and KHC respectively exemplifies the specificity of
kinesin-2 in KSHV transport and KHC in HSV-1 movement
along microtubules.
Though the observations seen with the shRNA mediated
knockdown of KIF3A/KHC on KSHV egress, seem to be
exciting, these however have to be interpreted cautiously. Down-
regulation of the kinesins could possibly have other off-target
effects on the viral or cellular components. This could be especially
true given the fact that kinesins are involved in cellular processes.
Possible deleterious effects on the viral processes associated with
the knockdown were ruled out from the observation that the levels
of viral DNA replication in cells expressing the KIF3A/KHC
shRNAs were similar to that seen in cells expressing the negative
control shRNA. More importantly, among the off-target effects on
the cells likely to impact on KSHV egress, would be any effects on
the microtubule structure. Earlier studies have shown that KIF3A
knockdown in mammalian cells do not affect the microtubule
architecture [45]. Thus with levels of viral DNA replication and
the microtubule architecture remaining unaffected, we could safely
conclude that the initial steps in virus assembly remain unaffected
by the knockdown. KIF3A down regulation has been shown to
produce slightly aberrant Golgi complex morphology in mamma-
lian cells [45]. This is not likely to be the reason for a decrease in
KSHV egress, as HSV-1 microtubule-dependent transport was
not significantly affected.
The association of KIF3A with the viral capsid-tegument
complexes was principally mediated by ORF45. Indeed, ORF45
was found to be tightly associated with the pelleted capsid complex
when purified virions treated with detergents (Triton X-100 plus
0.5% DOC) were subjected to high-speed centrifugation [9,17]. In
addition, the interactions of ORF45 with a multitude of tegument
proteins including ORF64 and ORF63 and capsid proteins like
ORF62 have been revealed in a virion-wide protein interaction
study from our laboratory [25]. Thus ORF45 being associated
tightly with the capsid-tegument complex is a probable component
of the inner tegument acquired early following exit of capsids from
the nuclear membrane hence is placed strategically to efficiently
position the viral capsid-tegument complexes onto KIF3A. Further
mapping studies by Y2H approaches, revealed that ORF45
interacted with other proteins like ORF64 and ORF 63 only
through its middle segment (spanning amino acids 115–332) (our
unpublished data). This suggested that ORF45 could possibly have
2 distinct interacting domains; the amino and carboxy terminal
ends that interact with KIF3A and the central domain interacting
with the other virion proteins. This possibly ensures a more
efficient binding of KIF3A to its binding sites on ORF45.
In related herpesviruses like HSV-1, recruitment of KHC by
tegument proteins contributes to transportation of viral complexes
toward viral egress [36–38,42]. Contrastingly our study findings
point out that KSHV recruits KIF3A (through ORF45) for
transportation of viral capsid-tegument complexes. This finding
seems highly intriguing, the most plausible explanation for the
differences in the recruited kinesins could reside in the highly
divergent tail (cargo-binding) domain of the kinesins that are
known to specify distinct set of cargoes for each of them. Given the
fact that ORF45, a protein with no homologs in alpha and beta-
herpesviruses interacts with KIF3A, it is tempting to speculate that
KIF3A might be uniquely adapted to mediate transportation of
KSHV and other gamma-herpesviruses.
Two observations in our study substantiated the finding that
microtubules serve as the major cellular highway for KIF3A to
transport the viral capsid-tegument complexes. Treatment of
BCBL-1 cells with a MT depolymerizer nocodazole [29] caused
an appreciable decrease in virion production with drug removal
replenishing the viral titer levels. Further confocal microscopic
images revealed the association of viral particles with MTs
following reactivation. Similar requirements of an intact microtu-
bular structure for transport of virus complexes toward egress have
been shown for other herpesviruses like HSV and PrV [11,26–
28,38]. Revelation of the process of KSHV particle transport on
microtubules during virion assembly provides novel strategies for
halting viral replication and treating KSHV-associated diseases.
For example, microtubule structure in cells can be disrupted by
reagents like nocodazole (an MT destablizer) or taxol (MT
stablizer) as many of such reagents are shown to suppress
loading control. (B) Effects of KIF3A and KHC silencing on KSHV egress. BCBL-1 cells stably expressing the control shRNA, KIF3A shRNAs (clones #s1 –
4), and KHC shRNAs (clone #s 1–3) were treated with TPA (20 ng/ml) to induce KSHV lytic replication. Four days post-induction, extracellular KSHV
virions were harvested and concentrated 100-fold. Virus stocks were treated with Turbo DNase I, and viral genomic DNA were extracted. KSHV
genomic DNA concentration was estimated by a real-time PCR along with external standards of known concentrations of the viral DNA with primers
against the ORF73 gene. Viral titers were presented as viral DNA copy numbers per milliliter (ml) of the supernatant. (C) Effects of lentivirus
transduction on KSHV viral DNA replication. BCBL-1 cells stably expressing the KIF3A and KHC shRNAs were treated with TPA (20 ng/ml) to induce
KSHV lytic replication. Two days post-induction, cells were collected and total intracellular DNAs were extracted with the Qiagen DNeasy kit.
Intracellular viral DNAs were measured by a real-time PCR with primers directed to the ORF73 gene from a 100 ng input DNA. The viral genome
copies were normalized to 20,000 copies of GAPDH.
doi:10.1371/journal.ppat.1000332.g007
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PLoS Pathogens | www.plospathogens.org 12 March 2009 | Volume 5 | Issue 3 | e1000332Figure 8. Model for transport of KSHV capsid-tegument complexes following viral reactivation. Newly synthesized nucleocapsids exit
out of the nuclear compartment wherein they acquire the tegument proteins including ORF45. ORF45 on the viral particles binds to KIF3A, docking
the entire viral capsid-tegument complexes onto it. The complexes are then transported along microtubules either to trans-Golgi vesicles (TGN) or
cell membrane for further envelopment and viral egress.
doi:10.1371/journal.ppat.1000332.g008
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new drugs for KS and reveal pharmacological mechanism of the
drugs.
In this study we thus report on the transportation of KSHV viral
complexes along microtubules by KIF3A, a kinesin motor which
to the best of our knowledge has thus far not been implicated in
virus transport. This finding could thus lead researchers to
investigate similar roles of KIF3A in transportation of other
viruses. Furthermore, our study by delineating the role of ORF45
has helped unravel the initial pathways of KSHV transportation
toward egress. However further assembly and transportation of
mature enveloped virions still remains an enigma. This final
transportation phase could probably involve recruitment of kinesin
motors either by the glycoptotein cytoplasmic tails or by
membrane associated tegument proteins as suggested for HSV-1
[38]. On these lines, a recent study has identified an interaction of
HSV-2 membrane-associated tegument protein pUL56 with
KIF1A [37]. This interaction has been speculated to contribute
to the axonal transport of viral glycoprotein-containing vesicles.
Another study has revealed an association of KIF5B with
enveloped HSV-1 containing in abundance the amyloid precursor
protein (APP), a kinesin cellular receptor [42]. Though these
studies provide interesting observations, further investigation of
this phenomenon is warranted. The sequence of events involved in
transportation of KSHV viral complexes to the nucleus following
cell entry also needs investigation with specific focus on the virion
proteins and the cellular motors involved. Information garnered
from all these sources would definitely help in providing the entire
picture of the KSHV lytic life cycle starting from viral entry and
ending with viral egress. Lastly, the significance of the less studied
KSHV tegument has been exemplified by the pivotal and multi
functional roles of ORF45. This should pave way for future studies
examining functional roles of even the other tegument proteins in
the viral life cycle.
Materials and Methods
Cells and viruses
BCBL-1, a latent KSHV-infected primary effusion lymphoma
cell line was maintained in RPMI 1640. Human embryonic kidney
(HEK) 293T cells were maintained in Dulbecco’s modified Eagle
medium (DMEM). All cultures were supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and antibiotics.
Plasmid constructs
The prey plasmids used for Y2H were constructed by cloning
either the full-length or the different truncation/deletion mutants
of KSHV ORF45 and KIF3A (Figure 2A) in pACT2 vector
(between the BamHI & XhoI sites) in frame with the vector’s GAL4
Activation Domain (AD). The deletion mutants of both ORF45
and KIF3A were generated with a PCR-based mutagenesis
system, ExSite (Stratagene) using a pair of phosphorylated
oligonucleotides in opposite directions with either pACT2-
ORF45 or the pACT2-KIF3A as the template plasmids
respectively. Bait plasmids were constructed by cloning either
the full-length KIF3A or the ORF45 sequences in pAS2-1 vector
in frame with GAL4 DNA-binding domain (DBD).
For co-immunoprecipitation (co-IP) assays, full-length and the
different truncation mutants of KSHV ORF45 (Figure 2A) were
PCR amplified and cloned into pCMV-Tag2 vector (Stratagene)
between the BamHI & XhoI sites. The deletion mutants of ORF45
were constructed using the ExSite (Stratagene) system with a pair
of phosphorylated oligonucleotides using pCMV-Tag2-ORF45 as
the template.
Yeast two-hybrid (Y2H) screen and assays
The ORF45 and KIF3A prey plasmids were tested for their
ability to interact with KIF3A and ORF45 bait plasmids
respectively by a yeast-two hybrid screen, performed with the
Matchmaker system (CLONTECH). The haploid yeast strain
MATa MaV103 (gift from Dr. Marc Vidal at the Massachusetts
General Hospital) was co-transformed with prey and bait plasmids
using lithium acetate. Yeast transformants positive for prey-bait
interaction were selected on plates lacking leucine, tryptophan and
histidine but containing 3-Amino-1,2,4-triazole (3-AT) and
subsequently assayed for b-galactosidase activity using the
standard colony-filter assay (as per the Clontech Yeast Protocols
handbook).
DNA transfection
293T cells grown in 100 mm dishes to 70% confluency were
transfected with 10 mg of expression plasmid by the calcium
phosphate transfection method. BCBL-1 cells were transfected by
electroporation. Plasmid DNAs were mixed with BCBL-1 cells in
OPTI-MEM medium (Gibco-BRL) and electroporated (200 V,
960 mF) with a Genepulser II (Bio-Rad, Hercules, Calif.).
Electroporated cells were then transferred to RPMI 1640 medium
supplemented with 10% serum and maintained for the time as
indicated.
Co-immunoprecipitation (co-IP) assay and
immunoblotting
BCBL-1 cells were induced with TPA (20 ng/ml) for 48 hours.
Cell lysates prepared in ice-cold lysis buffer [25] were homoge-
nized and clarified by high-speed centrifugation at 4uC and
subjected to an immunoprecipitation with mouse-monoclonal
anti-ORF45 [9] or rabbit-polyclonal anti-KIF3A (Sigma) antibod-
ies for 2 hours or overnight at 4uC. Immunoprecipitated
complexes were thoroughly washed with cold lysis buffer,
resuspended in 100 ml of sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) loading buffer, boiled for 10 mins
and loaded onto SDS-PAGE gels (Invitrogen). The primary
antibodies used for Western blotting were mouse monoclonal anti-
ORF45 and rabbit-polyclonal anti-KIF3A. Subsequent incubation
with secondary antibodies and detection was done as earlier [25].
Similarly, transfected 293T cells were collected forty-eight hours
post-transfection, lysed with ice-cold lysis buffer and homogenized
as above. Immunoprecipitation was performed as above by
incubating lysates with anti-flag M2 Affinity gel (A2220, Sigma).
Immunoprecipitated protein complexes were washed and run on a
SDS-PAGE. Primary antibodies used for Western blotting were
the mouse monoclonal anti-Flag M2 antibody (Sigma) and the
rabbit-polyclonal anti-KIF3A (Sigma). Incubation with secondary
antibodies and subsequent detection was performed as earlier [25].
Assay of interaction of KIF3A and viral particles using
BAC-cloned wild-type KSHV and ORF45-null mutant
viruses
Frozen glycerol stocks of the BAC36 (BAC-cloned wild-type
KSHV) and BAC-stop45 (ORF45-null mutant virus) [18] were
retrieved and BAC DNA was prepared with the large construct kit
(QIAGEN). The freshly prepared DNA was transfected into 293T
cells, stable BAC-293T monolayers generated through hygro-
mycin selection and induced with TPA. Cells lysates collected
forty-eight hours post-induction were incubated with rabbit-
polyclonal anti-KIF3A antibody (Sigma) for 2 hours or overnight
at 4uC, followed by incubation with Protein G agarose beads
(Invitrogen) for 2 hours at 4uC. A reaction with 2 ml of rabbit IgG
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addition to KIF3A, the IP complexes were also analysed for the
different virion protein using specific antibodies including mouse
monoclonal anti-ORF45, rabbit-polyclonal anti-ORF64 and
mouse polyclonal anti-ORF33 [9], mouse anti-ORF62 IgM (gift
from Dr. Z.H. Zhou at UCLA), rabbit-polyclonal anti-ORF65,
rabbit-polyclonal anti-gB (gift from Dr. Johnan Kaleeba at the
Uniformed Services University of the Health Sciences), mouse
monoclonal anti-gH (gifts from Dr. Gary Cohen at Penn).
Treatment of BCBL-1 cells with cytoskeletal disrupting
agent nocodazole
BCBL-1 cells were treated with increasing concentrations (0.5,
5.0, 10.0 mM) of the microtubule depolymerizing drug nocodazole
(Sigma) at 37uC for 1 hour and then induced with 20 ng/ml TPA
for 4 days. For nocadazole washout experiments, cells were treated
with 5 mM of the drug, washed twice with PBS, once with serum-
free medium to ensure complete removal of the drug and then
induced with TPA. Post-induction, virions were purified and
pelleted from the medium supernatant as detailed earlier [9] and
were resuspended in 16phosphate-buffered saline (PBS) in 1/100
of the original volume. Concentrated viruses were first treated with
Turbo DNase I (Ambion) at 37uC for 1 h to remove any
contaminating DNA outside viral particles. Viral DNA was
liberated by digestion with lysis buffer (AL) and proteinase K
(supplied with the DNeasy tissue kit, Qiagen) and extracted with
phenol-chloroform. Extracted DNA was precipitated with ice-cold
ethanol, and the final DNA pellet was dissolved in TE buffer.
Copy numbers of KSHV genomic DNA were estimated by real-
time DNA PCR with a Roche LightCycler and the LightCycler
FastStart DNA Master
Plus SYBR green kit with primers directed to
LANA [46]. Viral DNA copy numbers were calculated from
external standards of known concentrations of BAC36 DNA. A
serial dilution of a known amount of BAC36 DNA was used to
construct a standard curve. Copy numbers were normalized and
were expressed as copy number per milliliter of supernatant.
Immunofluorescence assay (IFA)
BCBL-1 cells were induced with TPA (20 ng/ml) for 48 hours.
Cells were washed with PBS, fixed with 2% paraformaldehyde in
PBS, and spun onto Shandon double cytoslides at 1,000 rpm for
5 min. Cells then were permeabilized in 0.2% Triton X-100 in
PBS for 20 min on ice and subjected to a double-labeled IFA with
mouse monoclonal anti-ORF45 [9] and rabbit-polyclonal anti-
KIF3A (Sigma) antibodies. Fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG and Texas Red-conjugated anti-rabbit
IgG (Vector Laboratories, Inc.) were used as the respective
secondary antibodies. Slides were examined with a Leica TCS
SPII confocal laser scanning system. The 2 channels were
recorded simultaneously and/or sequentially and controlled for
possible breakthrough between the green and red channels.
For visualization of the viral particles along MTs, induced, fixed
and permeablized BCBL-1 cells were subjected to a double labeled
IFA. MTs were stained with mouse monoclonal anti-tubulin
antibody (Sigma) whilst the viral particles were stained with rabbit-
polyclonal anti-ORF65 (capsid antibody). Goat anti-mouse IgG-
Alexa Flour 488 (Molecular Probes, Invitrogen) and goat anti-
rabbit–IgG-Texas Red (Vector Laboratories) were used as the
respective secondary antibodies. Double staining was then
examined under a confocal microscope (Leica TCS SPII confocal
laser scanning system) by the use of the 495- and 590-nm bands of
laser lines from a water-cooled argon-krypton laser under an oil
immersion objective. Channel recording and control of data
acquisition was done as earlier. A series of optical sections of the
image were collected at increasing intervals of 0.32 mm from the
bottom to the top. This was employed for the reconstruction of a
3-D representation of the specimen on the graphics computer with
the LCS 3D software (Leica Microsystems). Digital images
obtained were cropped and adjusted for contrast with Photoshop.
Dominant negative mutant assay
The C-terminal region of KIF3A (spanning amino acids 409–
702) was PCR amplified and cloned into the pCMV 3-Tag- (flag)
vector between BamHI and XhoI sites. This was designated the
KIF3A DN mutant. Increasing concentrations (0.5, 1.0, 2.0 or
10.0 mg) of this mutant plasmid along with 10 mg of pCR3.1-
ORF50 [47] or empty pCR3.1 vector were mixed and
electroporated into BCBL-1 cells as mentioned earlier and
maintained for 4 days. ORF50 encodes for the replication
transctivator (RTA) essential for induction of cells into the lytic
phase [48].
293T cells were also transfected with increasing concentrations
(0.5, 1.0, 2.0, 10.0 mg) of the KIF3A DN plasmid by the calcium
phosphate transfection method. Following transfection, cells were
infected with concentrated KSHV (at 50 genomes per cell) plus
Polybrene (4 mg/ml). Virus inocula was then removed, cells were
washed twice and replaced with fresh medium containing FBS.
Forty-eight hours following infection monolayers were induced
with 20 ng/ml TPA (for 4 days). Extracellular KSHV virions were
purified and collected from either induced BCBL-1 or 293T cells.
DNA extraction from intact virions and subsequent KSHV
genomic DNA quantitation was performed as detailed earlier.
KIF3A DN mutant transfected 293T cells were also infected
with HSV-1 (5 Pfu/cell) and incubated at 37uC (for 1 hour). Cells
were washed twice and replenished with fresh medium containing
FBS. At different time points (18, 24 and 36 hours) following
infection, the medium was clarified, extracellular virions were
collected and DNA isolated. Copy numbers of HSV-1 genomic
DNA was estimated by a real-time PCR with primers directed
against the HSV-1 UL30 gene [49]. For external standards, HSV-
1 genomic DNA was extracted from the HSV-1 KOS strain
(kindly provided by Dr. Gary Cohen at Penn) and quantitated. A
serial dilution of a known concentration of this DNA was used to
construct a standard curve.
Knockdown of KIF3 and KHC expression using shRNA-
mediated silencing technique
Two Mission shRNA gene sets against human KIF3A and
KIF5B/KHC respectively were purchased from Sigma-Aldrich.
The KIF3A set consists of four individual shRNA lentiviral vectors
in pLKO.1-puro plasmids against different target sites of KIF3A
(with Clone IDs NM_007054.4-2737s1c1, -2134s1c1, -781s1c1, -
1945s1c1 – for convenience sake referred as KIF3A shRNA clone
#s 1, 2, 3, 4). The KIF5B/KHC set contains five clones targeting
different sites of KIF5B/KHC (with Clone IDs NM_004521.1-
3461s1c1, -1376s1c1, -1904s1c1, -391s1c1, -842s1c1 – referred as
KHC shRNA clone #s 1, 2, 3, 4, 5). A control vector (a non-
targeting shRNA that activates the RNAi pathway without
targeting any known human gene, SHC002) was also purchased
(Sigma-Aldrich). Each of the shRNA vectors as well as the control
vector was used to prepare lentiviral stocks by cotransfecting 293T
cells with the shRNA vector and two packaging vectors
(pHR’8.2DR and pCMV-VSV-G) at a ratio of 4:3:1 respectively.
. Three days post-transfection, the culture media that contain
shRNA retroviruses were harvested, centrifuged (5006g for
10 min at 4uC), and filtered through a 0.45 mm filter to ensure
removal of any non adherent cells.
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lentivirus stocks in the presence of polybrene (8 mg/ml). Trans-
duced cells were selected with puromycin (2 mg/ml) for a week.
Efficacies of these shRNAs in knockdown of the respective proteins
were assayed by Western blot with specific antibodies. BCBL-1
cells stably expressing the KIF3A/KHC/control shRNAs were
treated with TPA (20 ng/ml) to induce KSHV lytic replication.
Four days post-induction, extracellular KSHV virions were
collected. DNA extraction from intact virions and viral titer
estimation were performed as detailed earlier.
Sub-confluent 293T monolayer cells were also transduced with
the lentivirus stocks in the presence of polybrene and selected with
puromycin as above. 293T cells stably expressing the KIF3A/
KHC/control shRNAs were infected with HSV-1 at an MOI of 5.
Twenty-four hours post-infection, the supernatant medium was
clarified, extracellular HSV-1 virions were pelleted and viral DNA
isolated. Viral titers were estimated by a real-time PCR as earlier.
Supporting Information
Figure S1 Knockdown of KIF3A and KHC by short-hairpin
RNA (shRNA)-mediated silencing and the effects on HSV-1 egress
and extracellular viral titers. (A) Inhibition efficiency of KIF3A
and KHC expression in 293T cells. Two sets of hsRNA constructs,
each consists of four individual shRNA lentiviral vectors in
pLKO.1-puro plasmids against different target sites of KIF3A
(KIF3A shRNA clone #s 1–4) and KHC (KHC shRNA clone #s
1–4), respectively, and a non-targeting control shRNA that
activates the RNAi pathway without targeting any known human
gene were introduced into 293T cells through lentiviral transduc-
tion in the presence of polybrene. Cells were selected through
puromycin (2 mg/ml) selection for a week and then tested for
effective knockdown of the respective proteins by a Western blot
(WB) performed on the whole cell extracts using anti- KIF3A
(rabbit-polyclonal, left panel) and KHC (rabbit-polyclonal, right
panel). A WB for b-actin protein detection was also performed as
an internal loading control. (B) Effects of KIF3A and KHC
silencing on HSV-1 egress. 293T cells stably expressing the control
shRNA, KIF3A shRNAs (clones #s 1–4), and KHC shRNAs
(clone #s 1–3) were infected with HSV-1 at MOI of 5.
Extracellular virions were collected at 24 hour post-infection.
HSV-1 genomic DNA was extracted and quantitated by a real-
time PCR along with external standards of known concentrations
of the viral DNA with primers directed against UL30 gene and
expressed as the respective viral DNA copy numbers per ml of the
supernatant.
Found at: doi:10.1371/journal.ppat.1000332.s001 (1.33 MB TIF)
Video S1 A reconstructed 3-D movie of a cell showing close
association of viral particles with microtubules. BCBL-1 cells
induced with TPA for 48 hours were fixed and permeablized.
MTs and viral capsids were stained with mouse monoclonal anti-
tubulin and rabbit-polyclonal anti-ORF65 antibodies, respectively,
with anti-mouse IgG-Alexa Flour 488 (green) and anti-rabbit/IgG-
Texas Red (red) secondary antibodies. Double staining was then
examined under a confocal microscope (Leica TCS SPII confocal
laser scanning system). A series of optical sections of the image
were collected at increasing intervals of 0.32 mm from the bottom
to the top. This was employed for the reconstruction of a 3-D
representation of the specimen on the graphics computer with the
LCS 3D software (Leica Microsystems).
Found at: doi:10.1371/journal.ppat.1000332.s002 (1.55 MB
MOV)
Video S2 A reconstructed 3-D movie of a cell following
nocodazole treatment. BCBL-1 cells treated with 5 mM nocoda-
zole were subsequently induced with TPA for 48 hours, fixed, and
permeablized. Microtubules and viral capsids were stained with
mouse monoclonal anti-tubulin and rabbit polyclonal anti-ORF65
antibodies, respectively, with anti-mouse IgG-Alexa Flour 488
(green) and anti-rabbit/IgG-Texas Red (red) secondary antibodies.
Double staining was then examined under a confocal microscope
(Leica TCS SPII confocal laser scanning system). A series of
optical sections of the image were collected at increasing intervals
of 0.32 mm from the bottom to the top. This was employed for the
reconstruction of a 3-D representation of the specimen on the
graphics computer with the LCS 3D software (Leica Micro-
systems).
Found at: doi:10.1371/journal.ppat.1000332.s003 (1.50 MB
MOV)
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